ODI PHARMA AB
ODI Pharma AB (publ), a pharmaceutical company, engages in the production and distribution of pharmaceutical cannabis and cosmetics products in Europe. It offers dried flowers; and cosmetics products under the Kandol brand. The company was founded in 2018 and is based in Stockholm, Sweden.
ODI PHARMA AB (6OD) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ODI PHARMA AB (6OD) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ODI PHARMA AB - Net Assets Trend (None–None)
This chart illustrates how ODI PHARMA AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ODI PHARMA AB (None–None)
The table below shows the annual net assets of ODI PHARMA AB from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ODI PHARMA AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ODI PHARMA AB Competitors by Market Cap
The table below lists competitors of ODI PHARMA AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PBS Finanse SA
WAR:PBF
|
$608.00K |
|
Enertopia Corporatio
OTCQB:ENRT
|
$609.29K |
|
LABOR. FARMAC. ROVI
BE:41L
|
$609.82K |
|
SYNAPTICS
BE:SJN
|
$609.97K |
|
Aranjin Resources Ltd
V:ARJN
|
$607.03K |
|
FullSix S.p.A
F:IA6
|
$606.45K |
|
ARCHER-DANIELS MID. - Dusseldorf Stock Exchang
DU:ADM
|
$606.28K |
|
Olivers Real Food Ltd
AU:OLI
|
$606.17K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ODI PHARMA AB's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ODI PHARMA AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ODI PHARMA AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ODI PHARMA AB's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ODI PHARMA AB (6OD) | €- | N/A | N/A | $607.60K |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $243.78K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.26K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $987.66 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $77.40 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $35.57 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.73 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |